Allergy Therapeutics PLC Positive data of Pollinex Quattro Grass vaccine
June 25 2018 - 2:52AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
25 June 2018
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Allergy Therapeutics announces publication of data demonstrating
long-lasting efficacy of Pollinex Quattro Grass vaccine in
Immunotherapy
25 June 2018 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, today announces the publication of positive data in the
journal Immunotherapy, demonstrating long-lasting efficacy of
Pollinex Quattro Grass in patients with grass pollen allergy.
Zielen et al., Long-term effect of monophosphoryl lipid A
adjuvanted specific immunotherapy in patients with grass pollen
allergy. doi; 10.2217/imt-2018-0004 (ePub ahead of print).
The observational study, led by Professor Stefan Zielen of the
Goethe University, Germany, focused on the long-term efficacy of
Pollinex Quattro Grass. Each of the clinical symptoms (runny nose,
sneezing and conjunctivitis) were statistically significantly
reduced in treated patients compared with controls without
allergen-specific immunotherapy. The study concluded that patients
treated with Pollinex Quattro Grass vaccine exhibited significant
and long-lasting symptom improvements 3-6 years after cessation of
treatment.
Professor Stefan Zielen, author of the paper commented; "We are
delighted with the publication of our observational study that
demonstrates the long-term effects of Pollinex Quattro Grass
immunotherapy. Our paper highlights the benefits that this
allergen-specific immunotherapy can offer allergy sufferers, in
terms of patient convenience, as well as the potential for positive
and long-lasting effects."
Manuel Llobet, CEO at Allergy Therapeutics, said: "This paper
validates earlier studies indicating Pollinex Quattro is disease
modifying for the many patients affected by grass allergy. Together
with the recently announced positive data from our Phase Grass G205
clinical study, we believe that we have a robust data set for our
suite of novel allergy product candidates. We look forward to
commencing further studies with the goal of developing a strong
allergy portfolio to patients globally, including in the
significant US market."
The data presented supports earlier studies investigating
Pollinex Quattro, Zielen et al., 2007(1) and Rabe et al 2017(2) .
Sustained efficacy according to European Medicine Agency criteria
in 3114 patients was shown in the 2007 Zielen paper(1) , where
after 3 years, improvement of symptoms was reported in more than
93% of patients and the consumption of anti-allergic medication
decreased in more than 75% of patients.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / David Daley
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
About Pollinex Quattro Grass
Pollinex Quattro Grass contains three distinct components:
allergoids, micro-crystalline tyrosine (MCT) and monophosphoryl
lipid A (MPL(R) ). Allergoids (natural allergens chemically
modified to form allergoids) exhibit reduced allergenicity that
improves safety and allows for delivery of higher doses. These are
combined with the depot adjuvant technology MCT to provide enhanced
immune exposure and further improved tolerability.
Finally, the immune response is enhanced and directed by the
adjuvant MPL(R) . MPL is a toll-like 4 receptor (TLR4) agonist
which is extensively used in the Group's allergy vaccine portfolio
and in infectious disease vaccines registered in the USA.
About US allergy market
The US allergy immunotherapy market, which is anticipated to be
the main market for this product, is estimated by the Group to be
worth $2 billion with potential peak grass vaccine sales of
$300-400 million per annum.
1- Zielan et al., Aller gologie, Jahrgang 30, Suppl. 1/2007, S1-S8.
2- Rabe, U et al. Allergo J Int (2017) 26: 147.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGURCQUPRUQA
(END) Dow Jones Newswires
June 25, 2018 02:52 ET (06:52 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024